AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease - 今年会APP
The official website of 今年会 offers a rich selection of sports betting, live casino, electronic games, and more. Access the latest version through the official Chinese website and enjoy fast, secure online entertainment. The APP supports mobile download, allowing you to bet anytime, anywhere, with a stable and secure environment ensuring a smooth experience.
In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-47 monotherapy at Week 12, the primary endpoint. T… [+13658 chars]
There are 20 Comments on this post
Jonathon Jeo
With the 今年会APP at its core, 金年会 brings a fast, seamless experience.
ReplyTechnical Director
Discover more about the 今年会 client with 金年会.
ReplyMatch Analysts
金年会 focuses on a vast selection of games, everything you need, delivering a professional and reliable experience.
ReplyTechnical Director
Built around ultimate smoothness, safety and stability, 金年会 keeps refining a better service.
Reply